Effective Strategies for Managing Severe Eosinophilic Asthma

When diagnosed with severe eosinophilic asthma, characterized by elevated eosinophil levels in the airways, medical professionals aim to control symptoms and reduce eosinophil counts. Lowering these cells helps improve breathing and quality of life. While standard asthma treatments often help, some patients develop resistance. Various options are available, including medications that prevent attacks and reduce lung inflammation. Recent advances involve biologic therapies—lab-engineered antibodies injected into patients—that target specific immune pathways involved in eosinophilia and asthma.

Benralizumab is an injectable monoclonal antibody that reduces the effects of Interleukin-5, a protein involved in eosinophil activity. Approved for patients over 12, it is often used alongside other asthma medications. Clinical trials show benralizumab can cut severe exacerbations by about 51%, decrease daily oral steroid use by 75%, and improve lung function significantly. Typical dosing involves monthly injections initially, then every eight weeks. Common side effects include allergic reactions, breathing issues, dizziness, swelling, rash, or hives. Patients should consult their doctor, especially if pregnant or nursing, before starting this medication.